机译:KRAS,BRAF和PIK3CA突变作为伊立替康和奥沙利铂难治性转移性结直肠癌患者西妥昔单抗疗效的预测指标的临床实用性
Department of Clinical Oncology Institute of Development Aging and Cancer Tohoku University">(1);
Department of Clinical Oncology Institute of Development Aging and Cancer Tohoku University">(1);
Department of Clinical Oncology Tohoku University Hospital">(2);
Department of Pathology Tohoku University Hospital">(3);
Department of Medical Oncology Sendai Medical Center">(5);
Department of Clinical Oncology South Miyagi Medical Center">(6);
Cancer Center Tohoku University Hospital">(4);
Department of Clinical Oncology Institute of Development Aging and Cancer Tohoku University">(1);
Department of Pathology Sendai Kousei Hospital">(7);
Department of Clinical Oncology Institute of Development Aging and Cancer Tohoku University">(1);
Department of Clinical Oncology Tohoku University Hospital">(2);
Department of Clinical Oncology Institute of Development Aging and Cancer Tohoku University">(1);
Department of Clinical Oncology Tohoku University Hospital">(2);
Cancer Center Tohoku University Hospital">(4);
Cetuximab; Colorectal cancer; KRAS; BRAF; PIK3CA;
机译:KRAS,BRAF和PIK3CA突变作为伊立替康和奥沙利铂难治性转移性结直肠癌患者西妥昔单抗疗效的预测指标的临床实用性
机译:KRAS,BRAF,NRAS和PIK3CA突变对西妥昔单抗联合化疗治疗难治性转移性结直肠癌疗效的影响:一项回顾性财团分析。
机译:6096 KRAS / BRAF突变频率作为日本大肠癌患者西妥昔单抗的预测指标
机译:使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA,BRAF,PIK3CA突变
机译:葡萄糖剥夺选择结直肠癌中的KRAS和BRAF突变。
机译:对日本转移性大肠癌患者KRASNRASBRAF和PIK3CA突变临床病理特征的回顾性观察研究
机译:对日本转移性大肠癌患者KRAS,NRAS,BRAF和PIK3CA突变临床病理特征的回顾性观察研究